|
Infants with diabetes insipidus
|
| bet | 638/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Infants with diabetes insipidus: the drug of choice for the treatment of diabetes insipidus is desmopressin (dDAVP), a synthetic analog of arginine vasopressin, but with a 2,000- to 3,000-fold lower vasopressor effect. An aqueous argipressin infusion should be considered in the initial management of post-surgical or post-traumatic DI. It has the advantage of having a relatively short half-life so that the dose can be titrated against the urine output. It has the disadvantage of requiring significant observation and adjustment of the infusion rate depending upon the hourly urine output. Management should be in PICU where monitoring and expertise are readily available. In children with DI secondary to brain injury, an initial infusion of aqueous argipressin 0.00025 to 0.001 units/kg/hour (0.25 to 1.0 milliunits/kg/hour titrated to urine output 2–3 ml/kg/hour, urine specific gravity 1.010–1.020 and serum sodium 140–145 mEq/L, was effective.8 Argipressin infusion can be used in infants with diabetes insipidus where dDAVP is not though appropriate. (LOE IV GOR C)
|
| |
